Xiaochun Xiong

Jiangsu Key Laboratory Of New Drug Research And Clinical Pharmacy
Xuzhou, 221004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Corrigendum to "Development of a potent BET inhibitor for the treatment of renal fibrosis" [Eur. J. Med. Chem., 295 (2025), 117822].

Corrigendum to "Development of a potent BET inhibitor for the treatment of renal fibrosis" [Eur. J. Med. Chem., 295 (2025), 117822].

Journal: European journal of medicinal chemistry

Published: August 20, 2026

Design and discovery of a novel interleukin-11 derived peptide with antagonistic activity for the treatment of renal fibrosis.

Design and discovery of a novel interleukin-11 derived peptide with antagonistic activity for the treatment of renal fibrosis.

Journal: Bioorganic chemistry

Published: January 16, 2026

De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy.

De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy.

Journal: Journal of medicinal chemistry

Published: September 18, 2025

Long-Acting and Stapled GLP-1R/GIPR/GCGR Triple Agonist for the Treatment of Obesity and Atherosclerosis.

Long-Acting and Stapled GLP-1R/GIPR/GCGR Triple Agonist for the Treatment of Obesity and Atherosclerosis.

Journal: Journal of medicinal chemistry

Published: July 24, 2025

Development of a Long-Acting Interleukin-11 Antagonist for the Treatment of Renal Fibrosis.

Development of a Long-Acting Interleukin-11 Antagonist for the Treatment of Renal Fibrosis.

Journal: Journal of medicinal chemistry

Published: April 08, 2025

Transforming bone cancer treatment: a comprehensive review of green-synthesized metal nanoparticles.

Transforming bone cancer treatment: a comprehensive review of green-synthesized metal nanoparticles.

Journal: Cancer cell international

Published: March 20, 2025

Development of a potent BET inhibitor for the treatment of renal fibrosis.

Development of a potent BET inhibitor for the treatment of renal fibrosis.

Journal: European journal of medicinal chemistry

Published: February 05, 2025

Structural basis of tolvaptan binding to the vasopressin V2 receptor.

Structural basis of tolvaptan binding to the vasopressin V2 receptor.

Journal: Acta pharmacologica Sinica

Published: April 15, 2024

Long-Residence Time Peptide Antagonist for the Vasopressin V2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease.

Long-Residence Time Peptide Antagonist for the Vasopressin V2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease.

Journal: Journal of medicinal chemistry

Published: March 20, 2024

Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease.

Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease.

Journal: Journal of medicinal chemistry

Published: May 17, 2022

Total synthesis of hapalindole-type natural products.

Total synthesis of hapalindole-type natural products.

Journal: Angewandte Chemie (International ed. in English)

Published: June 26, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026